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Abstract
Background: The discovery of the importance of angiogenesis in tumor growth has emphasized the need
to find specific vascular targets for tumor-targeted therapies. Previously, using phage display technology,
we identified the peptide GX1 as having the ability to target the gastric cancer vasculature. The present
study investigated the bioactivities of GX1, as well as its potential ability to cooperate with recombinant
mutant human tumor necrosis factor alpha (rmhTNFα), in gastric cancer therapy.
Results: Tetrazolium salt (MTT) assay showed that GX1 could inhibit cell proliferation of both human
umbilical vein endothelial cells (HUVEC) (44%) and HUVEC with tumor endothelium characteristics,
generated by culturing in tumor-conditioned medium (co-HUVEC) (62%). Flow-cytometry (FCM) and
western blot assays showed that GX1 increased the rate of apoptosis from 11% to 31% (p < 0.01) by up-
regulating caspase 3 expression level. A chorioallantoic membrane assay indicated that GX1 could
suppress neovascularization in vivo, with the microvessel count decreasing from 21 to 11 (p < 0.05). When
GX1 was fused to rmhTNFα, GX1-rmhTNFα selectively concentrated in the gastric cancer vasculature,
as shown by enzyme-linked immunosorbent assay, immunofluorescence and emission-computed
tomography. In vitro MTT and FCM assays showed that, compared to rmhTNFα alone, GX1-rmhTNFα
was more effective at suppressing co-HUVEC proliferation (45% vs. 61%, p < 0.05) and inducing apoptosis
(11% vs. 23%, p < 0.05). In a tumor formation test, GX1-rmhTNFα more effectively inhibited tumor
growth than rmhTNFα (tumor volume: 271 mm3 vs. 134 mm3, p < 0.05), with less systemic toxicity as
measured by body weight (20.57 g vs. 19.30 g, p < 0.05). These therapeutic effects may be mediated by
selectively enhanced tumor vascular permeability, as indicated by Evan's blue assay.
Conclusion: GX1 had both homing activity and the ability to inhibit vascular endothelial cell proliferation
in vitro and neovascularization in vivo. Furthermore, when GX1 was conjugated to rmhTNFα, the fusion
protein was selectively delivered to targeted tumor sites, significantly improving the anti-tumor activity of
rmhTNFα and decreasing systemic toxicity. These results demonstrate the potential of GX1 as a homing
peptide in vascular targeted therapy for gastric cancer.
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Background
Ever since the essential role of angiogenesis in tumor for-
mation and metastasis was proposed by Folkman in 1971,
increasing attention has been paid to vascular targeted
therapy [1-3]. The vasculature is an attractive target
because vascular endothelial cells are more genetically sta-
ble than tumor parenchymal cells and less likely to
acquire drug resistance, and vascular targets on endothe-
lial cells are readily accessible to systemically delivered
agents [4-6]. Based on these advantages, efforts have
focused on identifying specific molecules expressed on
the surface of tumor vascular endothelial and perivascular
cells [7,8]. Finding such tumor vascular targets may help
make anticancer drugs more selective, through their tar-
geted delivery, thus providing higher therapeutic effi-
ciency while simultaneously decreasing systemic toxicity.
With this goal, we previously used in vivo screening of a
phage-displayed peptide library to identify a cyclic 7-mer
peptide, CGNSNPKSC, called GX1, which binds specifi-
cally to the human gastric cancer vasculature [9]. Immu-
nohistochemical staining, enzyme-linked
immunosorbent assay (ELISA), and immunofluorescence
confirmed the targeting activity of GX1 peptide, indicating
that GX1 might be used as a novel vascular marker for
human gastric cancer [10]. The potential bioactivities that
might accompany the targeting function of GX1, and how
it might be combined with other agents for antitumor
therapy, are investigated here. We conducted a series of
tests to determine the effects of GX1 on vascular endothe-
lial cells, and on tumor angiogenesis and growth. In addi-
tion, we fused GX1 to recombinant mutant human tumor
necrosis factor (rmhTNFα), a variant of the TNFα cytokine
that is well known for its potent antitumor activity and is
less toxic than TNFα [11,12], to see if the fusion protein
could achieve synergistic therapeutic efficacy. These stud-
ies provide important preclinical evidence for the use of
GX1 in targeted antitumor therapy.
Results
GX1 inhibits endothelial cell proliferation in vitro by 
inducing apoptosis
GX1 was tested for its ability to inhibit both endothelial
cells and tumor cell proliferation by the tetrazolium salt
(MTT) assay. The results showed that GX1 could repro-
ducibly suppress, in dose-dependent manner, the prolifer-
ation of human umbilical vein endothelial cells (HUVEC)
and HUVEC with tumor endothelial cell characteristics
(co-HUVEC), generated by culturing the cells in tumor-
conditioned medium [13]. Differences in the relative cell
number between cells treated with GX1 and the control
peptide (Pep2) were significant at concentrations of 10,
25, 50, 75 and 100 μM for co-HUVEC (p < 0.01) (Figure
1A), and were significant at 75 and 100 μM for HUVEC (p
< 0.05) (Figure 1B). In addition, GX1-induced inhibitory
effects were more obvious in co-HUVEC than in the non-
tumor conditioned HUVEC (Figure 1C). In contrast, no
such differences were detectable in gastric adenocarci-
noma SGC7901 cells (Figure 1D), further demonstrating
the selectivity of GX1.
Subsequently using flow-cytometry (FCM), it was found
that GX1 (50 μM), but not Pep2 (50 μM), induced apop-
tosis in co-HUVEC compared to the phosphate-buffer
saline (PBS) control (apoptosis rate: 31.2% vs. 11.4%, p <
0.01) (Figure 1E). However, assessment of cell cycle distri-
bution by FCM showed no significant difference between
the test and control groups. These results indicated that
inhibition of vascular endothelial cell proliferation by
GX1 was, at least in part, through induction of apoptosis.
We further detected the expression level of the apoptosis
related molecule caspase 3 by western blot. As shown in
Figure 1F, the expression of cleaved caspase 3 was up-reg-
ulated in GX1 (50 μM) treated co-HUVEC. In contrast, no
changes were detected in Pep2 (50 μM) or PBS treated
cells. In brief, GX1 appeared to induce apoptosis of co-
HUVEC by up-regulating the expression of caspase 3.
GX1 inhibits angiogenesis in vivo by a chorioallantoic 
membrane (CAM) assay
Since GX1 could repress vascular endothelial cell prolifer-
ation in vitro, we carried out CAM assays to see if the pep-
tide could inhibit angiogenesis in vivo. Disruption of
angiogenesis was observed in GX1-treated chicken
embryos, with attenuated and tortuous microvessels in
the CAM and fewer angiogenic vessels contacting the disk,
when compared to the PBS control group. No significant
differences existed between the Pep 2 and PBS control
groups, with both showing well-developed and leaf vein-
like vascular nets (Figure 2).
GX1 conjugated to rmhTNFα concentrates in gastric 
cancer
In addition to proapoptotic and anti-angiogenic activity,
GX1 was also assessed for its ability to act as a targeting
delivery vector in combination therapy for gastric adeno-
carcinoma. GX1 was fused to rmhTNFα as previously
reported [14] and its tumor-targeted distribution was
investigated. ELISA was used to analyze the amount of
GX1-rmhTNFα in tumor and non-tumor tissues, and the
results showed that GX1-rmhTNFα accumulated in tumor
tissues over time. The radioactivity of GX1-rmhTNFα rela-
tive to rmhTNFα (GX1-rmhTNFα/rmhTNFα rate) signifi-
cantly increased in tumor tissue from 0.95 at 0.5 h to 3.84
at 2 h (p < 0.01). In contrast, this ratio decreased in liver
within 2 h after administration of the agent (p < 0.05),
and no evident trend was observed in other major organs
(Figure 3).
We took planar scintigrams of tumor-bearing mice
injected with 99Tcm-GX1-rmhTNFα, to further confirm the
in vivo tumor-targeting. Compared to 99Tcm-rmhTNFαBMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
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(Figure 4B, D), the radioactivity in tumor tissue was much
higher in the 99Tcm-GX1-rmhTNFα group (Figure 4A, C).
The tumor/muscle radioactivity ratios of 99Tcm-GX1-
rmhTNFα and 99Tcm-rmhTNFα were 8.24 and 1.42,
respectively, at 18 h (p < 0.05). Simultaneously, immun-
ofluorescence was used to detect the specific location of
GX1-rmhTNFα. GX1-rmhTNFα, but not rmhTNFα, was
found to co-localize with CD31 which was used as a pos-
itive control in tumor vasculature (Figure 4E-G). Collec-
tively, these results suggest that the fusion protein
acquired the ability to target tumor vessels and may lead
to more selective drug delivery to tumors.
GX1-rmhTNFα inhibits co-HUVEC proliferation in vitro by 
inducing apoptosis
The MTT assay was used to detect the effects of GX1-rmhT-
NFα on endothelial cell proliferation, and showed that
the fusion protein was significantly better at inhibiting co-
GX1 inhibits cell proliferation of both co-HUVEC and HUVEC through induction of apoptosis Figure 1
GX1 inhibits cell proliferation of both co-HUVEC and HUVEC through induction of apoptosis. GX1 was shown 
by MTT assay to suppress the proliferation of co-HUVEC (A) and HUVEC (B) in a dose-dependent manner. (C) GX1 had a 
greater inhibitory effect on co-HUVEC than HUVEC. (D) GX1 had no obvious effect on gastric adenocarcinoma SGC7901 
cells. (E) GX1 at 50 μM significantly enhanced apoptosis of co-HUVEC over PBS treatment. The results are reported as mean 
± SD of three independent experiments. Bars, SD. * p < 0.05, ** p < 0.01. (F) GX1 at 50 μM remarkably up-regulated caspase 3 
expression level.BMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
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HUVEC proliferation than rmhTNFα, with inhibition
rates of 61% vs. 45% at 10 μM (p < 0.05) (Figure 5A).
To address whether the decrease in cell number was due
to apoptosis induced by GX1-rmhTNFα, FCM was used to
determine the apoptosis rate in co-HUVEC. The results
showed that the apoptosis rates induced by 10 μM GX1-
rmhTNFα or rmhTNFα were 23.4% and 11.2% respec-
tively (p < 0.01) (Figure 5B). In contrast, no significant dif-
ferences in cell cycle distribution were detected between
the test and control groups. These results indicated that
inhibition of vascular endothelial cells by GX1-rmhTNFα
might be partly caused by induction of apoptosis.
Effects of GX1-rmhTNFα on tumor growth in vivo
Subsequently, using an in vivo tumor formation test, GX1-
rmhTNFα was assayed for its effects on tumor growth.
Nude mice bearing human gastric adenocarcinoma
xenografts were injected intravenously on alternate days
with GX1-rmhTNFα (0.5 mg/kg), rmhTNFα (0.5 mg/kg),
GX1 (0.25 mg/kg to account for its lower molecular
weight) or normal saline (NS). Mouse body weight, which
is used as a major indicator of TNF toxicity [11,15], and
tumor mass volumes were assessed over time. Tumor
growth was significantly delayed by GX1-rmhTNFα treat-
ment, and the average tumor volume of the GX1-rmhT-
NFα group was much smaller than that of the rmhTNFα
group (134.33 mm3 vs. 271.50 mm3, p < 0.05) (Figure
6A). In addition, at the end of the test, mice treated with
GX1-rmhTNFα had a higher average body weight than
those treated with rmhTNFα (20.57 g vs. 19.30 g, p < 0.05)
(Figure 6B), suggesting that the fusion protein had less
systemic toxicity than rmhTNFα alone.
Since TNFα is known to alter vascular barrier function, we
performed Evan's blue assay to assess the effect of GX1-
rmhTNFα on tumor perfusion. Compared to rmhTNFα-
treated mice, the GX1-rmhTNFα treated group showed a
greater leakage of Evan's blue dye in the tumor paren-
chyma. Differences were statistically significant at 0.5 mg/
kg (0.113 vs. 0.073, p < 0.05) (Figure 6C). We therefore
hypothesize that the GX1-rmhTNFα fusion protein selec-
tively increases tumor vascular permeability and leads to
higher local drug levels, which may play an important part
in the antitumor mechanism of GX1-rmhTNFα.
GX1 inhibits angiogenesis in CAM assay Figure 2
GX1 inhibits angiogenesis in CAM assay. (A-C) GX1 at 20 μg (50 μM) hampered neovascularization of fertilized eggs. 
Attenuated and tortuous microvessels are shown in the CAM, with fewer angiogenic vessels contacting the filter disks. (D) 
Number of microvessels contacting the disks. Bars, SD. * p < 0.05.BMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
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Discussion
To improve therapeutic indices and decrease systemic tox-
icity, more specific and selective anticancer agents that can
discriminate between tumor and nonmalignant cells are
urgently needed, along with the development of antitu-
mor radiochemotherapy [16-18]. The discovery that ang-
iogenesis plays a crucial role in tumor formation, and that
vascular targeting approaches exhibit the advantages of
easy accessibility and lower incidence of drug resistance,
provides a possible path to creating these new anticancer
agents [19,20]. Several studies have pursued this strategy,
including the application of phage display technology to
pan for peptides that bind specifically to defined tissue
targets [8,21]. Using this technique, several homing pep-
tides have been identified, including RGD, NGR and F3,
and many have showed promising results for imaging
diagnosis and treatment of various tumors in preclinical
or clinical investigations [22-25]. Furthermore, some of
these peptides have been conjugated to bioactive agents,
including drugs, cytokines, procoagulant factors, photo-
sensitizers and radionuclides, and have been included in
antineoplastic therapies. Initial results of these studies
showed more selective and targeted drug delivery and
fewer side effects [7,21,26,27]. However, to date, no
such peptide has been identified that targets human gas-
tric cancer.
Previously, we used in vivo screening of a phage displayed
peptide library to identify GX1, a cyclic 7-mer peptide
CGNSNPKSC that binds specifically to the human gastric
cancer vasculature [9]. Autoradiography on different cell
lines confirmed the targeting activity of GX1 toward the
gastric cancer vascular endothelium, by showing that the
binding affinity of GX1 was significantly higher in
HUVEC cultured in tumor-conditioned medium than in
HUVEC cultured in non-conditioned medium. No spe-
cific binding was observed in the human gastric carci-
noma cell line SGC7901 or in the immortalized gastric
epithelial cell line GES cells [28]. Furthermore, immuno-
histochemical staining and immunofluorescence showed
positive staining for GX1 in the vascular endothelium of
human gastric adenocarcinoma, but not in heart, liver,
muscle, spleen or normal gastric tissues [10,28]. In
another study, using single photon emission computed
tomography (SPECT), GX1 labelled with 99TcmO4
- (99Tcm
-GX1) was observed to concentrate in tumor xenografts in
nude mice [28]. Collectively, these results indicate that
GX1 is a novel vascular marker of human gastric cancer,
and may lead to a new way of imaging diagnosis and tar-
geted gastric cancer therapy.
Since GX1 selectively targeted the vascular endothelium of
gastric cancer, we investigated whether it had specific
effects on tumor angiogenesis and growth. In this study,
in addition to targeting, GX1 showed bioactivity by both
MTT and CAM assay, inhibiting vascular endothelial cell
proliferation and hampering neovascularization. To
probe into the possible mechanisms of these effects, the
cell cycle distribution, cell apoptosis and the expression
level of apoptosis related molecule caspase3 were detected
by FCM and western blot assays. Inhibition of vascular
endothelial cell proliferation by GX1 was observed, at
least in part, to be through the up-regulation of caspase 3
expression and the induction of apoptosis. Further tests
including RT-PCR and gene microarray are underway to
investigate the precise mechanisms.
In vitro analysis showed that HUVEC cultured in tumor-
conditioned media partially acquire the characteristics of
tumor vascular endothelial cells, such as enhanced tubule
formation, cell proliferation, and migration [13,29]. Fur-
thermore, some proteins like vascular endothelial growth
factor receptor and the integrin αvβ3 may be up-regulated
in co-HUVEC, as is the case for other cancer endothelia
[6,30]. These findings lead us to the hypothesis that GX1
receptors are up-regulated in co-HUVEC, reflecting the
case in tumor vessels, and that more receptors may lead to
greater selective affinity and stronger anticancer effects.
This hypothesis is consistent with the MTT assay results, in
which GX1 showed more significant inhibitory effects on
co-HUVEC than on the parental HUVEC culture that was
not exposed to tumor-conditioned medium.
To assess the possibility of using GX1 as a targeted delivery
vector in combination with another antitumor molecule
Distribution of GX1-rmhTNFα in various organs Figure 3
Distribution of GX1-rmhTNFα in various organs. 
GX1-rmhTNFα accumulated in tumor tissues over time and 
was gradually cleared from the liver. GX1-rmhTNFα/rmhT-
NFα rate = radioactivity of GX1-rmhTNFα relative to rmhT-
NFα. Bars, SD. *p < 0.05, **p < 0.01.BMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
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for treatment of gastric cancer, GX1 was conjugated to
rmhTNFα. TNFα is a well-known, antitumor cytokine
whose clinical application is hampered by severe systemic
toxicity [12,15]. The novel mutant cytokine rmhTNFα
shows higher antitumor efficacy and has been approved
for clinical use in China [12]. Our data showed that after
fusion to GX1, rmhTNFα was selectively delivered to tar-
get tumor vasculature sites. Most important, GX1-rmhT-
NFα delayed tumor growth in vivo, with less loss of body
weight compared to rmhTNFα alone (Figure 6A, B). These
results indicated that more targeted and efficient antitu-
mor activity might be achieved by combining GX1 with
other anti-tumor agents (e.g. rmhTNFα), for a significant
reduction in systemic toxicity.
Despite the encouraging results, some questions are still
open, such as what the receptor is for GX1 on vascular
endothelial cells, and how ligand-receptor interaction
interferes with tumor angiogenesis. Further studies are
underway to answer these questions, and several candi-
date receptor molecules have been obtained. Identifica-
tion of the GX1 receptor will be a great help in
understanding the mechanism of GX1 and will accelerate
the development of clinical applications for GX1 in diag-
nosis and targeted treatment of gastric cancer.
Conclusion
In conclusion, the data presented here, taken together
with previously published results, demonstrate that GX1
is a novel vascular marker of human gastric cancer. For the
first time GX1 is shown to have properties other than
homing, including proapoptotic effects on vascular
endothelial cells, and in vivo inhibition of neovasculariza-
tion. Furthermore, when conjugated to rmhTNFα, GX1
selectively delivered the fusion protein to target tumor
sites, leading to higher antitumor efficiency with less sys-
temic toxicity. These findings demonstrate great potential
for developing GX1 both as a targeted vector and as an
GX1-rmhTNFα selectively concentrates at gastric cancer cells Figure 4
GX1-rmhTNFα selectively concentrates at gastric cancer cells. 99Tcm-GX1-rmhTNFα remained in tumor tissue from 
2 h to 18 h after injection (A, C), while no such accumulation was seen in the 99Tcm-rmhTNFα group (B, D). Tumors are indi-
cated by arrows. (E) Positive staining of CD31 in tumor vasculature (200×). (F) FITC-labeled GX1-rmhTNFα bound specifically 
to tumor vasculature (200×). (G) GX1-rmhTNFα colocalized with CD31 in tumor vasculature (200×). Arrow indicates a posi-
tively stained microvessel.BMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
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antiangiogenic agent in the diagnosis and treatment of
human gastric cancer.
Methods
Reagents, antibodies and peptides
Growth factors and Evan's blue were purchased from
Sigma (St. Louis, USA). M200 basal culture media and
low serum growth supplement (LSGS) were from Cascade
Biologics (USA). Anti-CD31 polyclonal antibody was
from ABcam (USA) and anti-TNF monoclonal antibody
was from Sigma Aldrich (Saint Louis, USA).
GX1-rmhTNFα inhibits co-HUVEC proliferation through  induction of apoptosis Figure 5
GX1-rmhTNFα inhibits co-HUVEC proliferation 
through induction of apoptosis. (A) GX1-rmhTNFα at 
10 μM more strongly inhibited co-HUVEC proliferation than 
rmhTNFα. (B) GX1-rmhTNFα at 10 μM more strongly 
enhanced apoptosis of co-HUVEC than rmhTNFα. The 
results are reported as mean ± SD of three independent 
experiments. Bars, SD. * p < 0.05, **p < 0.01.
GX1-rmhTNFα inhibits tumor growth with decreased sys- temic toxicity by enhancing tumor vascular permeability Figure 6
GX1-rmhTNFα inhibits tumor growth with 
decreased systemic toxicity by enhancing tumor vas-
cular permeability. (A) GX1-rmhTNFα significantly 
delayed tumor growth. (B) GX1-rmhTNFα led to less weight 
loss than rmhTNFα. (C) GX1-rmhTNFα induced a greater 
leakage of the dye in the tumor parenchyma than rmhTNFα. 
Bars, SD. * p < 0.05, **p < 0.01.BMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
Page 8 of 10
(page number not for citation purposes)
GX1 peptide (CGNSNPKSC) was synthesized by GL Bio-
chem (Shanghai) Ltd. A control peptide (Pep2) was cre-
ated by randomly scrambling the amino acid sequence of
GX1 while maintaining the disulfide bond to preserve the
U-type structure (CNKSPSGNC). rmhTNFα was created
by standard recombinant DNA techniques [11,31,32].
The GX1-rmhTNFα fusion protein was prepared as previ-
ously described [14].
Cell cultures
HUVEC (Cascade Biologics, USA) and the human gastric
cancer cell line SGC7901 were cultured as described [28].
Tumor conditioned medium (TCM) was prepared by
incubating SGC7901 cells in M200 (free of LSGS) (~1 ×
106/ml) for 24 h. The medium was then removed, centri-
fuged (2000 × g, 10 min), filtered with a 0.22-μm filter
and diluted five times with M200 supplemented with
LSGS. Tumor endothelial cells were generated by incubat-
ing HUVEC in TCM [29]. All cells were cultured at 37°C
in a humidified chamber with 5% CO2.
MTT, FCM and western blot assays
Proliferation of HUVEC and SGC7901 cells treated with
various concentrations of tested agents was determined by
MTT assay as described [33].
Apoptosis of co-HUVEC was detected by FCM analysis as
described [34]. Cells were treated with GX1 (50 μM) or
GX1-rmhTNFα (10 μM) for 48 h. Pep2 (50 μM), PBS or
rmhTNFα (10 μM) were used as controls.
The expression level of caspase 3 was measured by western
blot assay. The cultured cells were lyzed in modified RIPA
buffer (0.05 M Tris-HCl, pH 7.4, 1% NP-40, 0.25% Na-
deoxycholate, 0.15 M NaCl, 0.001 M Na3VO4, 0.001 M
EDTA and 0.5% of protease inhibitor cocktail). The lysate
was centrifuged at 10,000 × g, 4°C for 10 minute, and the
supernatant was collected. Protein concentration was
determined by the BCA protein assay (Pierce, Rockford,
IL, USA). Proteins were separated by 10% SDS-PAGE and
were transferred to PVDF membrane. western blot analy-
sis was carried out using the following primary antibod-
ies: anti-cleavage caspase 3 antibody (1:500; Abnova
Corporation, Taipei, Taiwan) and anti-β-actin antibody
(1:1000; Santa Cruz Biotechnology, Santa Cruz, CA,
USA), followed by incubation with horseradish peroxi-
dase (HRP) conjugated secondary antibody (Santa Cruz
Biotechnology, Santa Cruz, CA, USA). The blots were vis-
ualized using enhanced chemiluminescence (ECL) kit
(Amersham Pharmacia Biotech, Arlington Heights, IL,
USA) according to manufacturer's instructions.
Chorioallantoic Membrane (CAM) assay
Fertilized White Leghorn chicken embryos were randomly
divided into three groups with seven embryos per group,
and collected on day 3 into sterile containers for subse-
quent incubation at 37°C, 5% CO2 for 6 days. On day 9,
sterilized Whatman filter discs impregnated with 10 μl
(20 μg) GX1 were placed on the CAM. Pep2 (20 μg) and
PBS were used as controls. On day 11, the CAM was cut,
fixed by acetone and viewed under a microscope. Neovas-
cularization around the disk was quantitated by determin-
ing the number of angiogenic vessels within the CAM
around the disk.
In vivo distribution of GX1- rmhTNFα by emission 
computed tomography (ECT)
In vivo distribution of GX1-rmhTNFα in different organs
of tumor-bearing nude mice was detected by enzyme-
linked immunosorbent assay (ELISA, see below) and ECT.
A suspension of SGC7901 cells was prepared at 1 × 107
cells/ml. A total of 0.2 ml of the cell suspension was
implanted subcutaneously in the right upper flank of 4-6
week-old male nude BALB/c mice (animal centre of
FMMU, Xi'an, Shannxi, China). Three weeks after injec-
tion, the mice were randomly divided into three groups
with six mice per group, and treated with 0.25 mg/kg of
GX1-rmhTNFα or rmhTNFα, or NS through the tail vein.
The agents were allowed to circulate for 0.5 h, 1 h and 2 h
before blood samples were taken from the eye, and
tumors and major organs were removed. Tissue samples
were homogenized and sonicated at 4°C, followed by
centrifugation for 10 min at 12,000 × g. The supernatant
was subjected to ELISA.
Simultaneously, GX1-rmhTNFα labeled with 99TcmO4 
-
was used for dynamic imaging in biodistribution stud-
ies[28]. Anesthetized animals were injected intravenously
with 200 μl  99Tcm-GX1-rmhTNFα or 99Tcm-rmhTNFα at
470-540 μCi per mouse. Planar and single-photon emis-
sion tomography images with a low-energy collimator
were obtained, with 200,000 counts acquired per image at
the indicated timepoints. Time-dependent biodistribu-
tion studies were carried out by sacrificing mice at 2, 8,
and 18 h after injection. Tissue samples were removed at
the end of the test. The radioactivity was determined with
a gamma counter and decay-corrected to the time of injec-
tion. Results were calculated as injected dose (ID) per
gram of wet tissue weight (ID/g tissue), converted to per-
cent. GX1-rmhTNFα/rmhTNFα radioactivity rates of vari-
ous tissues were determined from the corresponding ID/g
tissue values.
ELISA, immunohistochemical staining and 
immunofluorescence staining
The amount of GX1-rmhTNFα and rmhTNFα in tumor
and other organs was quantified by ELISA kit (Depart-
ment of Immunology, FMMU, Xi'an, Shannxi, China).
The optical density at 470 nm was measured with a micro-
plate reader (Bio-Rad Laboratories, Hercules, CA).BMC Cell Biology 2009, 10:63 http://www.biomedcentral.com/1471-2121/10/63
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Immunohistochemical staining was performed as
described [35] using anti-TNF monoclonal antibody and
anti-CD31 polyclonal antibody. For immunofluores-
cence, tumor sections were incubated with diluted anti-
TNF monoclonal antibodies and anti-CD31 polyclonal
antibodies at 4°C overnight, and then treated with rhod-
amine-conjugated goat anti-mouse IgG and fluorescein
isothiocyanate-conjugated goat anti-rabbit IgG at 1:200
for 1 h at room temperature. Sections were analyzed by
fluorescence microscopy.
Evan's blue assay
Twenty days after subcutaneous injection of SGC7901
cells, nude mice were intravenously treated with GX1-
rmhTNFα, with rmhTNFα and NS as controls. Two hours
later, the mice were intravenously injected with 0.1 ml
Evan's blue (Sigma, St. Louis, MO; 12.5 mg/ml). After 5
min, the animals were sacrificed and the tumors were
excised. Each tumor was weighed, homogenized, resus-
pended in cold PBS containing 1% Triton X-100 (1 ml/g),
and incubated for 1 h on ice. The suspension was centri-
fuged (14,000 × g, 4°C, 15 min), and the supernatant
mixed with trichloroacetic acid (10%, v/v). The product
was centrifuged again (14,000 × g, 4°C, 15 min) and the
absorbance at 405 nm of the supernatant was measured
using a spectrophotometer.
In vivo tumor formation assay
Seven days after injection of SGC7901 cells as described
above, nude mice were randomly divided into groups of
seven mice and treated with the indicated reagents on
alternate days. Tumor development was observed by
sequential caliper measurements of length (L) and width
(W). Tumor volume was calculated by the formula L ×
W2/2. After 20 days, the mice were killed and the tumors
were removed and weighed. All studies were performed
according to internationally recognized guidelines for ani-
mal care.
Statistical analysis
Each experiment was repeated at least three times. Numer-
ical data are presented as mean ± standard deviation (SD).
The difference between means was analyzed by ANOVA.
All statistical analyses were performed using SPSS11.0
software (Chicago, IL). Differences were considered statis-
tically significant when p < 0.05.
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